Drugs / ALS-L1023
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials | ||||||
| Phase 2 | NCT04342793 | Dec 2019 → May 2021 | metabolic dysfunction-associated steatohepatitis | AngioLab, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT03725501 | Dec 2018 → Jun 2021 | age-related macular degeneration | AngioLab, Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT01872182 | May 2013 → Jan 2015 | abdominal obesity-metabolic syndrome | Hanmi Pharmaceutical Company Limited | Terminated | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALS-L1023 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01872182 ↗ |
| Known as | ALS-L1023 tablet | “ALS-L1023 tablet” NCT04342793 ↗ |
| Route | Oral | “ALS-L1023 600 mg - Take 2 tablets orally twice a day.” NCT03725501 ↗ |